Kazakh scientists have begun the
second phase of testing a cancer drug. This stage will be more extensive,
taking place in three cities, including Almaty, Astana, and Pavlodar. Around
3,000 out of the 5,000 volunteers will participate in the clinical trials. The
Supreme Science and Technology Commission has allocated two billion tenge for
this purpose. Notably, a cancer drug developed in Kazakhstan successfully
passed the first phase of clinical trials. According to the country’s Ministry
of Science and Higher Education, 15 cancer patients participated, including
those with one of the most aggressive forms of stage IV colorectal cancer. By
the end of the trial, tumors had decreased by an average of one-third, which
scientists describe as an encouraging result. The cancer drug is set to be
submitted for registration in 2025.
